scholarly journals Acute inhibition of oestrogen biosynthesis does not affect serum leptin levels in young men

2000 ◽  
pp. 164-169 ◽  
Author(s):  
V Luukkaa ◽  
J Rouru ◽  
O Ahokoski ◽  
H Scheinin ◽  
K Irjala ◽  
...  
Keyword(s):  
Placebo Group ◽  
Aromatase Inhibitor ◽  
Young Men ◽  
Serum Testosterone ◽  
Enzyme Design ◽  
Double Blind ◽  
Blood Samples ◽  
Serum Leptin ◽  
Selective Blockade ◽  
Pre Treatment

OBJECTIVE: Leptin plays an important role in the regulation of reproduction. To explore the contribution of oestradiol to serum leptin levels in men, we measured the concentrations of serum leptin and insulin after inhibition of oestrogen biosynthesis by selective blockade of the aromatase enzyme. DESIGN: The study had a double-blind parallel group design. METHODS: The aromatase inhibitor, MPV 2213ad, was given to eight healthy male volunteers as a single dose of 100mg. Eight men received placebo. Serum leptin and insulin were determined from blood samples collected at 0800h, 1600h and 2000h both on the actual test day (day 0) and on the previous day (day -1), and from single blood samples taken in the morning of days 1, 2, 4 and 7. Changes in serum leptin were correlated with those seen in serum oestradiol, testosterone, LH, FSH, cortisol and aldosterone, which were determined earlier. RESULTS: After the aromatase inhibitor administration, mean serum oestradiol concentration was reduced by 74% from the baseline compared with a 19% reduction in the placebo group (P for difference <0.001), and returned to pre-treatment levels within four days. Despite marked changes in serum oestradiol and sustained elevations in serum testosterone, LH and FSH concentrations, serum leptin concentrations were similar in the group receiving the aromatase inhibitor and in the placebo group. We found a weak correlation between serum oestradiol and leptin, which could not be reproduced when the percentage changes in these variables were analysed. CONCLUSION: Marked short-term reduction in serum oestradiol concentration has no effect on serum leptin levels in young men.

scholarly journals Cognitive effects of aromatase inhibitor therapy in peripubertal boys

2010 ◽  
Vol 163 (1) ◽  
pp. 149-155 ◽  
Author(s):  
M Hero ◽  
S Maury ◽  
E Luotoniemi ◽  
E Service ◽  
L Dunkel
Keyword(s):  
Aromatase Inhibitor ◽  
Short Stature ◽  
Cognitive Performance ◽  
Verbal Memory ◽  
Memory Function ◽  
Serum Testosterone ◽  
High Serum ◽  
Cognitive Effects ◽  
Double Blind

ObjectiveAromatase inhibitors, blockers of oestrogen biosynthesis, have emerged as a new potential treatment modality for boys with short stature. The cognitive effects of such therapy are unknown. In this study, we explored the effects of aromatase inhibition on cognitive performance in peripubertal boys.DesignProspective, double-blind, randomised, placebo-controlled clinical study.MethodsTwenty-eight boys, aged 9.0–14.5 years, with idiopathic short stature were treated with the aromatase inhibitor letrozole (2.5 mg/day) or placebo, for 2 years. During the treatment, the progression of physical signs of puberty and the concentrations of sex hormones were followed up. A selection of cognitive tests, focusing on memory function, was administered to the participants at entry, at 12 months and at 24 months after the start of the treatment.ResultsLetrozole effectively inhibited the conversion of androgen to oestrogen, as indicated by high serum testosterone and low serum oestradiol concentrations in letrozole-treated boys who progressed into puberty. In both the groups, there was a gain in performance during the follow-up period in tests of verbal performance, in most of the tests of visuospatial performance and in some tests of verbal memory. No significant differences between the letrozole- and placebo-treated boys in development of cognitive performance were found in any of the tests during the follow-up period.ConclusionsOur results suggest that blockade of oestrogen biosynthesis with an aromatase inhibitor does not influence cognitive performance in peripubertal males.

scholarly journals Impact of an Herbal Dietary Supplement Containing Spilanthes acmella and Orchis latifolia on Testosterone in Young Men

2016 ◽  
Vol 8 (1) ◽  
pp. 28
Author(s):  
Ryan G. Moran ◽  
Alex T. VonSchulze ◽  
Richard J. Bloomer
Keyword(s):  
Nitric Oxide ◽  
Young Men ◽  
Moderate Increase ◽  
Herbal Preparation ◽  
Double Blind ◽  
Total Blood ◽  
Blood Samples ◽  
Healthy Men ◽  
Spilanthes Acmella ◽  
The Impact

Attention has been given recently to herbal dietary supplements proposed to elevate testosterone and nitric oxide. This study evaluated the impact of a supplement containing Spilanthes acmella extract and Orchis latifolia extract on total blood testosterone, cortisol, and nitrate/nitrite in healthy men. Methods: Thirteen men (25.0±1.0 years) were randomly assigned (double-blind, cross-over design) to ingest a supplement (containing Spilanthes acmella extract and Orchis latifolia extract) and a placebo daily for 14 days, with a 14-day washout period between assignments. Fasting blood samples were collected on the mornings of days 1, 4, 8, and 15 and analyzed for testosterone, cortisol, and nitrate/nitrite. On day 15, subjects ingested an acute dose of the supplement or placebo and blood was collected every 30 minutes for three hours, and analyzed for testosterone. Results: No increase of significance was noted for any biochemical variable (p>0.05). However, a mean increase in testosterone from day 1 to day 15 of 29% was observed for the 13 subjects when ingesting the supplement, with a mean increase of 56% noted when only considering the 8 subjects who “responded” to treatment. Cortisol was increased approximately 19% when subjects ingested the supplement, compared to only 9% with the placebo. Conclusion: Two weeks of supplementation with an herbal preparation containing Spilanthes acmella extract and Orchis latifolia extract can increase testosterone in selected young men. The supplement also results in a moderate increase in cortisol. Larger scale studies are needed to further evaluate the impact of this herbal combination on testosterone in men.

scholarly journals Acute hormonal response to sublingual androstenediol intake in young men

2002 ◽  
Vol 92 (1) ◽  
pp. 142-146 ◽  
Author(s):  
Gregory A. Brown ◽  
Emily R. Martini ◽  
B. Scott Roberts ◽  
Matthew D. Vukovich ◽  
Douglas S. King
Keyword(s):  
Peak Concentration ◽  
Young Men ◽  
Serum Testosterone ◽  
Free Testosterone ◽  
Total Testosterone ◽  
Serum Estradiol ◽  
Hormonal Response ◽  
Double Blind ◽  
First Pass ◽  
Serum Hormone

The effectiveness of orally ingested androstenediol in raising serum testosterone concentrations may be limited because of hepatic breakdown of the ingested androgens. Because androstenediol administered sublingually with cyclodextrin bypasses first-pass hepatic catabolism, we evaluated the acute hormonal response to sublingual cyclodextrin androstenediol supplement in young men. Eight men (22.9 ± 1.2 yr) experienced in strength training consumed either 20 mg androstenediol in a sublingual cyclodextrin tablet (Sl Diol) or placebo (Pl) separated by at least 1 wk in a randomized, double-blind, crossover manner. Blood samples were collected before supplementation and at 30-min intervals for 3 h after supplementation. Serum hormone concentrations did not change with Pl. Serum androstenedione concentrations were increased ( P < 0.05) above baseline (11.2 ± 1.1 nmol/l) with Sl Diol from 60 to 180 min after intake and reached a peak concentration of 25.2 ± 2.9 nmol/l at 120 min. Serum free testosterone concentrations were increased from 86.2 ± 9.1 pmol/l with Sl Diol from 30 to 180 min and reached a peak concentration of 175.4 ± 12.2 pmol/l at 60 min. Serum total testosterone concentrations increased above basal (25.6 ± 2.3 nmol/l) from 30 to 180 min with Sl Diol and reached a peak concentration of 47.9 + 2.9 nmol/l at 60 min. Serum estradiol concentrations were elevated ( P < 0.05) above baseline (0.08 ± 0.01 nmol/l) from 30 to 180 min with Sl Diol and reached 0.14 ± 0.02 nmol/l at 180 min. These data indicate that sublingual cyclodextrin androstenediol intake increases serum androstenedione, free testosterone, total testosterone, and estradiol concentrations.

Does Propranolol have an Antipsychotic Effect?

1986 ◽  
Vol 148 (6) ◽  
pp. 701-707 ◽  
Author(s):  
Rahul Manchanda ◽  
Steven R. Hirsch
Keyword(s):  
Placebo Group ◽  
Fixed Dose ◽  
Base Line ◽  
Double Blind Trial ◽  
Clinical Change ◽  
Double Blind ◽  
Initial Improvement ◽  
Pre Treatment ◽  
Group D ◽  
Pharmacological Basis

Thirty-six acute schizophrenics were randomly assigned to dextro (d)-propranolol or placebo in a double blind trial lasting four weeks. All patients had a fixed dose of haloperidol during the first week, which resulted in an initial improvement in both groups. Thereafter, a deterioration towards base-line was seen. Six patients on placebo, but none on propranolol were treatment failures at the end of three weeks (P < 0.001). Comparison of change in scores from week 2 to 4 showed significantly greater deterioration in the placebo group; d-propranolol thus had a better effect than placebo in sustaining the initial improvement with haloperidol. The overall magnitude of clinical change from pre-treatment scores is small, the majority of the patients showing little or no overall improvement. It is concluded that d-propranolol has a detectable therapeutic effect, which by inference must have a novel pharmacological basis, but this is not as potent as standard neuroleptics.

scholarly journals Prolonged Sleep Restriction Affects Glucose Metabolism in Healthy Young Men

2010 ◽  
Vol 2010 ◽  
pp. 1-7 ◽  
Author(s):  
Wessel M. A. van Leeuwen ◽  
Christer Hublin ◽  
Mikael Sallinen ◽  
Mikko Härmä ◽  
Ari Hirvonen ◽  
...  
Keyword(s):  
Young Men ◽  
Sleep Restriction ◽  
Control Group ◽  
Blood Samples ◽  
Serum Leptin ◽  
Recovery Sleep ◽  
Glucose Ratio ◽  
Increased Risk ◽  
Develop Type

This study identifies the effects of sleep restriction and subsequent recovery sleep on glucose homeostasis, serum leptin levels, and feelings of subjective satiety. Twenty-three healthy young men were allocated to a control group (CON) or an experimental (EXP) group. After two nights of 8 h in bed (baseline, BL), EXP spent 4 h in bed for five days (sleep restriction, SR), followed by two nights of 8 h (recovery, REC). CON spent 8 h in bed throughout the study. Blood samples were taken after the BL, SR, and REC period. In EXP, insulin and insulin-to-glucose ratio increased after SR. IGF-1 levels increased after REC. Leptin levels were elevated after both SR and REC; subjective satiety remained unaffected. No changes were observed in CON. The observed increase of serum IGF-1 and insulin-to-glucose ratio indicates that sleep restriction may result in an increased risk to develop type 2 diabetes.

scholarly journals The effects of the aromatase inhibitor anastrozole on bone metabolism and cardiovascular risk indices in ovariectomized, androgen-treated female-to-male transsexuals

2006 ◽  
Vol 154 (4) ◽  
pp. 569-575 ◽  
Author(s):  
Mathijs C M Bunck ◽  
Arno W F T Toorians ◽  
Paul Lips ◽  
Louis J G Gooren
Keyword(s):  
Aromatase Inhibitor ◽  
Bone Metabolism ◽  
Serum Testosterone ◽  
Treated Group ◽  
Feedback Signal ◽  
Negative Effects ◽  
Estrogen Deprivation ◽  
Double Blind ◽  
The Metabolic Syndrome ◽  
Risk Indices

Objective: Cases of men with estrogen resistance and aromatase deficiency have highlighted the effects of estrogens on bone metabolism, the cardiovascular system and biochemical variables of the metabolic syndrome. In eugonadal men, administration of an aromatase inhibitor induces a substantial elevation of LH and testosterone due to the decreased negative-feedback signal of estrogen and may thwart the interpretation of results. As there is no gonad for LH to act on, no increase of serum testosterone concentration will be seen in female-to-male transssexuals. The aim of this study was to investigate the effects of estrogen deprivation on bone metabolism and vascular parameters without the interference of counter-regulatory effects as seen in eugonadal men. Design: Thirty ovariectomized female-to-male transsexuals participated in this double-blind, randomized trial. During 3 months, subjects received the aromatase inhibitor anastrozole 1 mg/day (n = 16) or a placebo (n = 14) in addition to parenteral testosterone esters (Sustanon 250 every 2 weeks). Results: Serum 17β-estradiol (E2) concentration fell significantly from 134.0 ± 78.8 to 77.7 ± 130.6 pmol/l compared with placebo (P < 0.01). LH and FSH levels rose without the rise of testosterone levels observed in eugonadal men. Within the placebo group, E2 remained at baseline levels. Of the endpoint variables measured (bone metabolism and vascular parameters) no significant changes were observed compared with placebo, or within the anastrozole-treated group. Conclusions: These results may indicate that the negative effects of estrogen deprivation in men only become manifest when the concentration falls below the levels induced by our intervention with anastrozole (77 pmol/l). This assumption is supported by the observation in the anastrozole group that, although effects of the reduction of serum E2 on vascular parameters could not be demonstrated in subjects as a group, there was a correlation between individual serum E2 and several vascular parameters.

scholarly journals Efficacy and safety of cumaru syrup as complementary therapy in mild persistent asthma: a double-blind, randomized, placebo-controlled study

2012 ◽  
Vol 48 (4) ◽  
pp. 629-637
Author(s):  
Elisete Mendes Carvalho ◽  
Gilmara Holanda da Cunha ◽  
Francisco Vagnaldo Fechine ◽  
Célia Regina Amaral Uchôa ◽  
Manoel Odorico de Moraes Filho ◽  
...  
Keyword(s):  
Placebo Group ◽  
Adverse Events ◽  
Persistent Asthma ◽  
Complementary Therapy ◽  
Post Treatment ◽  
Controlled Study ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Pre Treatment ◽  
Mild Persistent Asthma

Amburana cearensis is a medicinal plant known as "cumaru". It is used in Northeast Brazil in the treatment of respiratory diseases. This was a randomized, double-blind, placebo-controlled study, with the aim of evaluating the efficacy and safety of cumaru syrup as complementary therapy in mild persistent asthma. The study consisted of 3 phases, pre-treatment, treatment and post-treatment. The primary efficacy outcome was comparison of the changes reported by patients of the cumaru and placebo groups after treatment, using the "Asthma Quality of Life Questionnaire" (AQLQ). The secondary outcome was the effect of cumaru syrup on lung function based on spirometry. The results showed that in the cumaru group, the proportion of patients who had global improvement in asthma symptoms was significantly greater (61.90%, P=0.0009) than in the placebo group (9.52%). Only the spirometric parameters Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 second (FEV1) showed significant intergroup differences in post-treatment (P<0.05). The hematological and serum chemistry tests performed in the pre-treatment and post-treatment showed no statistically significant differences (P>0.05). Adverse events were reported by 3 patients (14.29%) in the cumaru group and 3 patients (14.29%) in the placebo group. All adverse events were considered non-serious and mild.

The Effect of Warfarin Sodium on the Duration of Platelet Aggregation

1967 ◽  
Vol 18 (03/04) ◽  
pp. 766-778 ◽  
Author(s):  
H. J Knieriem ◽  
A. B Chandler
Keyword(s):  
Platelet Count ◽  
Placebo Group ◽  
Platelet Aggregation ◽  
Prothrombin Time ◽  
Platelet Rich Plasma ◽  
Healthy Adults ◽  
Double Blind Study ◽  
Double Blind ◽  
Warfarin Sodium

SummaryThe effect of the administration of warfarin sodium (Coumadin®) on the duration of platelet aggregation in vitro was studied. Coumadin was given for 4 consecutive days to 10 healthy adults who were followed over a period of 9 days. The duration of adenosine diphosphate-induced platelet aggregation in platelet-rich plasma, the prothrombin time, and the platelet count of platelet-rich plasma were measured. Four other healthy adults received placebos and participated in a double-blind study with those receiving Coumadin.Although administration of Coumadin caused a prolongation of the prothrombin time to 2 or 21/2 times the normal value, a decrease in the duration of platelet aggregation was not observed. In most individuals who received Coumadin an increase in the duration of platelet aggregation occurred. The effect of Coumadin on platelet aggregation was not consistently related to the prothrombin time or to the platelet count. In the placebo group there was a distinct relation between the duration of platelet aggregation and the platelet count in platelet-rich plasma.The mean increase in the duration of platelet aggregation when compared to the control value before medication with Coumadin was 37.7%. In the placebo group there was a mean increase of 8.4%. The difference between the two groups is significant (p <0.001). Increased duration of platelet aggregation also occurred in two individuals who received Coumadin over a period of 10 and 16 days respectively.

Double-blind, randomized controlled trial of tranexamic acid in minor lumbar spine surgery: no effect on operative time, intraoperative blood loss, or complications

2019 ◽  
Vol 31 (2) ◽  
pp. 194-200 ◽  
Author(s):  
Signe Elmose ◽  
Mikkel Ø. Andersen ◽  
Else Bay Andresen ◽  
Leah Yacat Carreon
Keyword(s):  
Placebo Group ◽  
Lumbar Spine ◽  
Blood Loss ◽  
Tranexamic Acid ◽  
Spine Surgery ◽  
Operative Time ◽  
Decompressive Surgery ◽  
Lumbar Spine Surgery ◽  
Intraoperative Blood Loss ◽  
Double Blind

OBJECTIVEThe purpose of this study was to investigate the effect of tranexamic acid (TXA) compared to placebo in low-risk adult patients undergoing elective minor lumbar spine surgery—specifically with respect to operative time, estimated blood loss, and complications. Studies have shown that TXA reduces blood loss during major spine surgery. There have been no previous studies on the effect of TXA in minor lumbar spine surgery in which these variables have been evaluated.METHODSThe authors enrolled patients with ASA grades 1 to 2 scheduled to undergo lumbar decompressive surgery at Middelfart Hospital into a double-blind, randomized, placebo-controlled, parallel-group study. Patients with thromboembolic disease, coagulopathy, hypersensitivity to TXA, or a history of convulsion were excluded. Patients were randomly assigned, in blocks of 10, to one of 2 groups, TXA or placebo. Anticoagulation therapy was discontinued 2–7 days preoperatively. Prior to the incision, patients received either a bolus of TXA (10 mg/kg) or an equivalent volume of saline solution (placebo). Independent t-tests were used to compare differences between the 2 groups, with statistical significance set at p < 0.05.RESULTSOf the 250 patients enrolled, 17 patients were excluded, leaving 233 cases for analysis (117 in the TXA group and 116 in the placebo group). The demographics of the 2 groups were similar, except for a higher proportion of women in the TXA group (TXA 50% vs placebo 32%, p = 0.017). There was no significant between-groups difference in operative time (49.53 ± 18.26 vs 54.74 ± 24.49 minutes for TXA and placebo, respectively; p = 0.108) or intraoperative blood loss (55.87 ± 48.48 vs 69.14 ± 83.47 ml for TXA and placebo, respectively; p = 0.702). Postoperative blood loss measured from drain output was 62% significantly lower in the TXA group (13.03 ± 21.82 ml) than in the placebo group (34.61 ± 44.38 ml) (p < 0.001). There was no significant difference in number of dural lesions or postoperative spinal epidural hematomas, and there were no thromboembolic events.CONCLUSIONSTranexamic acid did not have a statistically significant effect on operative time, intraoperative blood loss, or complications. This study gives no evidence to support the routine use of TXA during minor lumbar decompressive surgery.Clinical trial registration no.: NCT03714360 (clinicaltrials.gov)

Sign in / Sign up

Export Citation Format

Share Document